Literature DB >> 23871784

Acute and 13 weeks subchronic toxicological evaluation of naringin in Sprague-Dawley rats.

Peibo Li1, Sheng Wang, Xiaolin Guan, Bin Liu, Yonggang Wang, Ke Xu, Wei Peng, Weiwei Su, Kejian Zhang.   

Abstract

Naringin is widely distributed in plant foods and has not previously been evaluated for safety through standard in vivo toxicological studies. In the present study, acute and subchronic oral toxicity studies of naringin were designed and conducted in Sprague-Dawley (SD) rats. Acute oral administration of naringin was done as a single bolus dose up to 16 g/kg and subchronic toxicity study for 13 weeks was done by oral administration at doses of 0 (control), 50, 250 and 1250 mg/kg in SD rats. There were no mortality, adverse clinical signs, abnormal changes in body weights or food consumption, toxicologically relevant changes in hematology, clinical biochemistry and macroscopic findings during 14 days of the acute toxicity study. During the subchronic oral toxicity study, no mortality and toxicologically significant changes in clinical signs, food consumption, opthalmoscopic examination, hematology, clinical biochemistry, serum sex hormone, macroscopic findings, organ weights and histopathological examination except for slight body weight decrease were noted and attributed to naringin administration. These observations suggest that naringin is practically non-toxic for SD rats in oral acute toxicity study and the no-observed-adverse-effect-level (NOAEL) of naringin in rats is greater than 1250 mg/kg/day when administered orally for 13 consecutive weeks.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute oral toxicity; Naringin; Sprague-Dawley rats; Subchronic toxicological evaluation

Mesh:

Substances:

Year:  2013        PMID: 23871784     DOI: 10.1016/j.fct.2013.07.019

Source DB:  PubMed          Journal:  Food Chem Toxicol        ISSN: 0278-6915            Impact factor:   6.023


  11 in total

1.  Assessment of the feed additive consisting of naringin for all animal species for the renewal of its authorisation (HealthTech Bio Actives, S.L.U. (HTBA)).

Authors:  Vasileios Bampidis; Giovanna Azimonti; Maria de Lourdes Bastos; Henrik Christensen; Birgit Dusemund; Mojca Fašmon Durjava; Maryline Kouba; Marta López-Alonso; Secundino López Puente; Francesca Marcon; Baltasar Mayo; Alena Pechová; Mariana Petkova; Fernando Ramos; Yolanda Sanz; Roberto Edoardo Villa; Ruud Woutersen; Paul George Brantom; Johannes Westendorf; Jaume Galobart; Paola Manini; Fabiola Pizzo
Journal:  EFSA J       Date:  2022-04-22

2.  Erythrocyte Storage Lesion Improvements Mediated by Naringin Screened from Vegetable/Fruit Juice Using Cell Extract and HPLC-MS.

Authors:  Yuqi She; Qiong Liu; Xiyue Xiong; Ning Li; Jian Zhang
Journal:  J Anal Methods Chem       Date:  2022-04-26       Impact factor: 2.594

Review 3.  Nephroprotective activity of naringin against chemical-induced toxicity and renal ischemia/reperfusion injury: A review.

Authors:  Negin Amini; Maryam Maleki; Mohammad Badavi
Journal:  Avicenna J Phytomed       Date:  2022 Jul-Aug

4.  Natural dietary compound naringin prevents azoxymethane/dextran sodium sulfate-induced chronic colorectal inflammation and carcinogenesis in mice.

Authors:  Yu-Sheng Zhang; Feng Wang; Shu-Xiang Cui; Xian-Jun Qu
Journal:  Cancer Biol Ther       Date:  2018-04-25       Impact factor: 4.742

Review 5.  A Review of Natural Stimulant and Non-stimulant Thermogenic Agents.

Authors:  Sidney J Stohs; Vladimir Badmaev
Journal:  Phytother Res       Date:  2016-02-09       Impact factor: 5.878

6.  Polymeric micelles for potentiated antiulcer and anticancer activities of naringin.

Authors:  Elham Abdelmonem Mohamed; Irhan Ibrahim Abu Hashim; Rehab Mohammad Yusif; Ahmed Abdel Aziz Shaaban; Ahmed Ramadan El-Sheakh; Mohammed Fawzy Hamed; Farid Abd Elreheem Badria
Journal:  Int J Nanomedicine       Date:  2018-02-19

7.  A Systematic Review of the Preventive and Therapeutic Effects of Naringin Against Human Malignancies.

Authors:  Maryam Ghanbari-Movahed; Gloria Jackson; Mohammad Hosein Farzaei; Anupam Bishayee
Journal:  Front Pharmacol       Date:  2021-03-29       Impact factor: 5.810

8.  Naringin Inhibits Apoptosis Induced by Cyclic Stretch in Rat Annular Cells and Partially Attenuates Disc Degeneration by Inhibiting the ROS/NF-κB Pathway.

Authors:  Yue-Hui Zhang; Wen-Ji Shangguan; Zhi-Jun Zhao; Fu-Chao Zhou; Hai-Tao Liu; Zhi-Hui Liang; Jia Song; Jiang Shao
Journal:  Oxid Med Cell Longev       Date:  2022-02-23       Impact factor: 6.543

Review 9.  Naringin and Naringenin: Their Mechanisms of Action and the Potential Anticancer Activities.

Authors:  Jolita Stabrauskiene; Dalia M Kopustinskiene; Robertas Lazauskas; Jurga Bernatoniene
Journal:  Biomedicines       Date:  2022-07-13

10.  Pharmacokinetics and Metabolism of Naringin and Active Metabolite Naringenin in Rats, Dogs, Humans, and the Differences Between Species.

Authors:  Yang Bai; Wei Peng; Cuiping Yang; Wei Zou; Menghua Liu; Hao Wu; Loudi Fan; Peibo Li; Xuan Zeng; Weiwei Su
Journal:  Front Pharmacol       Date:  2020-03-27       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.